United States Food and Drug Administration
"United States Food and Drug Administration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
| Descriptor ID |
D014486
|
| MeSH Number(s) |
I01.409.418.750.600.650.760 N03.540.348.500.500.600.650.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "United States Food and Drug Administration".
Below are MeSH descriptors whose meaning is more specific than "United States Food and Drug Administration".
This graph shows the total number of publications written about "United States Food and Drug Administration" by people in this website by year, and whether "United States Food and Drug Administration" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "United States Food and Drug Administration" by people in Profiles.
-
Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders. Mol Ther. 2022 07 06; 30(7):2416-2428.
-
Off-label use of aducanumab for cerebral amyloid angiopathy. Lancet Neurol. 2021 08; 20(8):596-597.
-
Pediatric contrast-enhanced ultrasound: shedding light on the pursuit of approval in the United States. Pediatr Radiol. 2021 Nov; 51(12):2128-2138.
-
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer. Clin Cancer Res. 2021 04 15; 27(8):2126-2129.
-
Drug Development 101: A Primer. Int J Toxicol. 2020 Sep/Oct; 39(5):379-396.
-
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer. Ther Innov Regul Sci. 2020 09; 54(5):1208-1214.
-
The Bretylium Saga: A Novel "Old Drug" for Cardiac Resuscitation. Am J Cardiol. 2020 05 15; 125(10):1596-1598.
-
A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol. 2019 09; 123(3):232-239.
-
Physician Guidance on the Use of Off-Labeled Drugs in Intrathecal Drug Delivery Systems for Chronic Pain. Neuromodulation. 2019 10; 22(7):765-768.
-
Assessment of Obstetric and Gynecologic Food and Drug Administration Device Approvals and Recalls. J Minim Invasive Gynecol. 2018 Nov - Dec; 25(7):1281-1288.